JP4458844B2 - pgsBCA、ポリ−γ−グルタミン酸シンテターゼをコードする遺伝子を有する表面発現用のベクター、及びこれを用いた標的タンパク質の微生物表面発現方法 - Google Patents
pgsBCA、ポリ−γ−グルタミン酸シンテターゼをコードする遺伝子を有する表面発現用のベクター、及びこれを用いた標的タンパク質の微生物表面発現方法 Download PDFInfo
- Publication number
- JP4458844B2 JP4458844B2 JP2003519489A JP2003519489A JP4458844B2 JP 4458844 B2 JP4458844 B2 JP 4458844B2 JP 2003519489 A JP2003519489 A JP 2003519489A JP 2003519489 A JP2003519489 A JP 2003519489A JP 4458844 B2 JP4458844 B2 JP 4458844B2
- Authority
- JP
- Japan
- Prior art keywords
- expression vector
- gene
- gram
- protein
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 240
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 118
- 238000000034 method Methods 0.000 title claims abstract description 40
- 108090000364 Ligases Proteins 0.000 title claims abstract description 13
- 102000003960 Ligases Human genes 0.000 title claims abstract description 11
- 239000013598 vector Substances 0.000 title abstract description 39
- 230000000813 microbial effect Effects 0.000 title description 3
- 239000013604 expression vector Substances 0.000 claims abstract description 257
- 244000005700 microbiome Species 0.000 claims abstract description 94
- 210000004027 cell Anatomy 0.000 claims description 177
- 101150076330 pgsA gene Proteins 0.000 claims description 76
- 108091007433 antigens Proteins 0.000 claims description 75
- 101100059000 Bacillus subtilis (strain 168) capA gene Proteins 0.000 claims description 66
- 101100083407 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) pgsA1 gene Proteins 0.000 claims description 66
- 239000000427 antigen Substances 0.000 claims description 65
- 102000036639 antigens Human genes 0.000 claims description 65
- 241000894006 Bacteria Species 0.000 claims description 32
- 101100219452 Bacillus subtilis (strain 168) capC gene Proteins 0.000 claims description 23
- 241000192125 Firmicutes Species 0.000 claims description 16
- 101100059011 Bacillus subtilis (strain 168) capB gene Proteins 0.000 claims description 13
- 101150103033 lpxB gene Proteins 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 229930195712 glutamate Natural products 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 96
- 238000003259 recombinant expression Methods 0.000 description 89
- 101710137302 Surface antigen S Proteins 0.000 description 88
- 230000015572 biosynthetic process Effects 0.000 description 75
- 238000003786 synthesis reaction Methods 0.000 description 74
- 239000004220 glutamic acid Substances 0.000 description 73
- 230000000890 antigenic effect Effects 0.000 description 72
- 241000588724 Escherichia coli Species 0.000 description 66
- 108010052285 Membrane Proteins Proteins 0.000 description 66
- 241000700721 Hepatitis B virus Species 0.000 description 65
- 230000003472 neutralizing effect Effects 0.000 description 59
- 102000018697 Membrane Proteins Human genes 0.000 description 57
- 239000012528 membrane Substances 0.000 description 49
- 108091008146 restriction endonucleases Proteins 0.000 description 46
- 210000004899 c-terminal region Anatomy 0.000 description 36
- 238000001262 western blot Methods 0.000 description 32
- 241000186660 Lactobacillus Species 0.000 description 30
- 229940039696 lactobacillus Drugs 0.000 description 30
- 238000003752 polymerase chain reaction Methods 0.000 description 28
- 101710116435 Outer membrane protein Proteins 0.000 description 27
- 108091034117 Oligonucleotide Proteins 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 239000004367 Lipase Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 241000193830 Bacillus <bacterium> Species 0.000 description 18
- 108020004705 Codon Proteins 0.000 description 18
- 108020001507 fusion proteins Proteins 0.000 description 17
- 102000037865 fusion proteins Human genes 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 16
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 16
- 229960005486 vaccine Drugs 0.000 description 16
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 14
- 241000607142 Salmonella Species 0.000 description 14
- 239000007853 buffer solution Substances 0.000 description 14
- 108700023418 Amidases Proteins 0.000 description 13
- 244000199866 Lactobacillus casei Species 0.000 description 13
- 238000010276 construction Methods 0.000 description 13
- 108090001060 Lipase Proteins 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- 235000013958 Lactobacillus casei Nutrition 0.000 description 11
- 239000013599 cloning vector Substances 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 229940017800 lactobacillus casei Drugs 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 10
- 102000004882 Lipase Human genes 0.000 description 10
- 102000005922 amidase Human genes 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 210000002421 cell wall Anatomy 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 235000019421 lipase Nutrition 0.000 description 9
- 210000004897 n-terminal region Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 101710141454 Nucleoprotein Proteins 0.000 description 6
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 210000004020 intracellular membrane Anatomy 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108010061100 Nucleoproteins Proteins 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical class O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101150062031 L gene Proteins 0.000 description 3
- 102000011931 Nucleoproteins Human genes 0.000 description 3
- 101710178358 Peptidoglycan-associated lipoprotein Proteins 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 108700017737 hepatitis B virus L Proteins 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 244000102216 Crateva tapia Species 0.000 description 2
- 235000003495 Crateva tapia Nutrition 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 2
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 108010085318 carboxymethylcellulase Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940093609 tricaprylin Drugs 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 101000992180 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) Outer membrane protein Omp38 Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 108010071023 Bacterial Outer Membrane Proteins Proteins 0.000 description 1
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001086530 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Outer membrane protein P5 Proteins 0.000 description 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
- 244000084296 Hernandia moerenhoutiana Species 0.000 description 1
- 235000010044 Hernandia moerenhoutiana Nutrition 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 108010036940 Levansucrase Proteins 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 101800000021 N-terminal protease Proteins 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191982 Staphylococcus hyicus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 108010083364 chungkookjang Proteins 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108010072250 fimbrillin Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006910 ice nucleation Effects 0.000 description 1
- 108010063679 ice nucleation protein Proteins 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 229940071204 lauryl sarcosinate Drugs 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1288—Transferases for other substituted phosphate groups (2.7.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01133—Xylosylprotein 4-beta-galactosyltransferase (2.4.1.133)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/08—Transferases for other substituted phosphate groups (2.7.8)
- C12Y207/08005—CDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase (2.7.8.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20010048373 | 2001-08-10 | ||
| PCT/KR2002/001522 WO2003014360A1 (en) | 2001-08-10 | 2002-08-09 | SURFACE EXPRESSION VECTORS HAVING pgsBCA, THE GENE CODING POLY-GAMMA-GLUTAMATE SYNTHETASE, AND A METHOD FOR EXPRESSION OF TARGET PROTEIN AT THE SURFACE OF MICROORGANISM USING THE VECTOR |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005500054A JP2005500054A (ja) | 2005-01-06 |
| JP2005500054A5 JP2005500054A5 (enExample) | 2006-01-12 |
| JP4458844B2 true JP4458844B2 (ja) | 2010-04-28 |
Family
ID=19713096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003519489A Expired - Fee Related JP4458844B2 (ja) | 2001-08-10 | 2002-08-09 | pgsBCA、ポリ−γ−グルタミン酸シンテターゼをコードする遺伝子を有する表面発現用のベクター、及びこれを用いた標的タンパク質の微生物表面発現方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7553636B2 (enExample) |
| EP (1) | EP1421195B1 (enExample) |
| JP (1) | JP4458844B2 (enExample) |
| KR (1) | KR100469800B1 (enExample) |
| CN (1) | CN1311082C (enExample) |
| AT (1) | ATE342990T1 (enExample) |
| DE (1) | DE60215521T2 (enExample) |
| WO (1) | WO2003014360A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100525759B1 (ko) * | 2002-10-17 | 2005-11-03 | 한국생명공학연구원 | 바실러스 속 균주 유래의 폴리 감마 글루탐산합성유전자를 이용한 펩타이드 항생물질 P5와Anal3의 표면 발현 방법 및 그의 용도 |
| CN100543140C (zh) | 2002-10-17 | 2009-09-23 | 生物领先公司 | 抗hpv疫苗的载体以及该载体转化的微生物 |
| RU2332457C2 (ru) * | 2003-06-04 | 2008-08-27 | Байолидерс Корпорейшн | Вектор, обеспечивающий экспрессию антигена вируса sars на поверхности клеток, и микроорганизмы, трансформированные этим вектором |
| KR20050079162A (ko) * | 2004-02-04 | 2005-08-09 | 주식회사 바이오리더스 | 파보바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 |
| US7255855B2 (en) * | 2004-02-27 | 2007-08-14 | Bioleaders Corporation | Surface expression method of peptides P5 and Anal3 using the gene encoding poly-gamma-glutamate synthetase |
| JP2005312426A (ja) * | 2004-03-31 | 2005-11-10 | Bioleaders Japan:Kk | タンパク質を表層提示する大腸菌 |
| JPWO2006117927A1 (ja) * | 2005-03-04 | 2008-12-18 | サントリー株式会社 | ポリグルタミン酸を産生する形質転換植物 |
| JP2006262724A (ja) * | 2005-03-22 | 2006-10-05 | Kobe Univ | タンパク質高発現乳酸菌 |
| JPWO2006126682A1 (ja) * | 2005-05-27 | 2008-12-25 | 財団法人化学及血清療法研究所 | アルツハイマー病の予防・治療用ワクチン |
| KR100872042B1 (ko) * | 2005-09-14 | 2008-12-05 | 주식회사 바이오리더스 | 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물 |
| KR100578395B1 (ko) * | 2005-11-11 | 2006-05-10 | 주식회사 바이오리더스 | 면역기능이 강화된 사균화 유산균 제제 및 그 제조방법 |
| KR100782332B1 (ko) * | 2006-01-23 | 2007-12-06 | 주식회사 바이오리더스 | 새우 흰 반점 바이러스 항원의 표면 발현벡터 및 이에 의해형질전환된 미생물 |
| KR100985914B1 (ko) * | 2006-12-13 | 2010-10-08 | 주식회사 바이오리더스 | 간암 특이 항원인 알파페토단백질의 표면발현벡터 및 이에의해 형질전환된 미생물 |
| KR100972843B1 (ko) | 2007-03-22 | 2010-07-28 | 주식회사 바이오리더스 | 신규 항시적 고발현 프로모터 및 그 용도 |
| KR100857861B1 (ko) * | 2007-10-15 | 2008-09-11 | 주식회사 바이오리더스 | Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물 |
| KR101471043B1 (ko) | 2009-01-08 | 2014-12-09 | 주식회사 바이오리더스 | 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균 |
| KR101564084B1 (ko) | 2009-01-08 | 2015-10-29 | 주식회사 바이오리더스 | repE 변이유전자를 함유하는 항시적 고발현 벡터 |
| JP5669361B2 (ja) * | 2009-03-17 | 2015-02-12 | 花王株式会社 | ポリ−ガンマ−グルタミン酸の調整方法 |
| JP5599153B2 (ja) * | 2009-03-17 | 2014-10-01 | 花王株式会社 | ポリ−ガンマ−グルタミン酸の製造方法 |
| EP2479270B1 (en) | 2009-09-17 | 2016-04-06 | Morishita Jintan Co., Ltd. | Gene expressing a bifidobacterium surface-presented fusion protein |
| JP5846523B2 (ja) * | 2010-11-18 | 2016-01-20 | 国立大学法人神戸大学 | βグルコシダーゼを発現する大腸菌 |
| JP2014210747A (ja) | 2013-04-19 | 2014-11-13 | アンジェスMg株式会社 | 細胞性免疫誘導能が改善された経口ワクチン |
| CN103555720B (zh) * | 2013-11-19 | 2015-08-19 | 湖北工业大学 | 一种具有生产和回收纤维素内切酶双重功能的酵母菌株的构建 |
| CN108350411B (zh) | 2015-06-25 | 2021-06-22 | 白川利朗 | 口服肿瘤疫苗 |
| EP3560513A4 (en) | 2016-12-26 | 2020-10-14 | National University Corporation Kobe University | ANTICANCER THERAPY USING A COMBINATION OF AN ORAL TUMOR VACCINE AND AN IMMUNOSUPPRESSION INHIBITOR |
| KR20200000972A (ko) * | 2018-06-26 | 2020-01-06 | 주식회사 바이오리더스 | 바실러스 속 균주 유래의 폴리감마글루탐산 합성유전자를 이용한 표면발현벡터 및 이를 이용한 단백질의 미생물표면 발현 방법 |
| JP7170129B2 (ja) * | 2018-10-10 | 2022-11-11 | バイオリーダース コーポレイション | ラクトバチルス・カゼイ由来の二種類のプロモーターを用いた二種の目的タンパク質の同時表面発現ベクター、およびこれを用いたタンパク質の微生物表面発現方法 |
| CN113330119B (zh) * | 2018-10-10 | 2024-07-12 | 生物领先公司 | 使用源自干酪乳杆菌的半乳糖变旋酶基因启动子用于组成型高表达的表面表达载体及其用途 |
| CN111593029B (zh) * | 2020-05-29 | 2022-05-17 | 江西省科学院微生物研究所 | 一种催化活性提高的γ-聚谷氨酸合成酶复合体及其编码基因 |
| CN113512562B (zh) * | 2021-04-28 | 2022-05-17 | 齐鲁工业大学 | γ-聚谷氨酸在植物中异源合成提高植物抗逆性和产量的方法 |
| CN114702559A (zh) * | 2022-04-02 | 2022-07-05 | 江西师范大学 | 枯草芽孢杆菌蛋白PgsA及其在表面展示系统中的应用 |
| KR20240053728A (ko) | 2022-10-17 | 2024-04-25 | 주식회사 퓨처앤텍 | 세포외막 지질단백질 PrsA 발현계를 이용한 세포표면 대량발현 기술 |
| CN118956803A (zh) * | 2022-11-22 | 2024-11-15 | 中国农业科学院茶叶研究所 | 茶树甲基化儿茶素合成酶CsFAOMT2、编码基因及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
| US5356797A (en) * | 1991-11-15 | 1994-10-18 | Board Of Regents, The University Of Texas | Membrane expression of heterologous genes |
| WO1993024636A1 (en) | 1992-05-29 | 1993-12-09 | The University Of British Columbia | Use of protein oprf for bacterial cell surface expression of oligopeptides |
| AU692140B2 (en) | 1992-11-03 | 1998-06-04 | Staffan Normark | Fibronectin binding protein as well as its preparation |
| DE4243770A1 (de) * | 1992-12-23 | 1994-06-30 | Behringwerke Ag | Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung |
| EP0711303B2 (en) | 1993-07-30 | 2009-06-10 | Affymax, Inc. | Biotinylation of proteins |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| KR0185335B1 (ko) * | 1996-04-02 | 1999-04-01 | 김은영 | 표면 발현 벡터 및 이를 이용한 단백질의 미생물 표면 발현 방법 |
| JP2001017182A (ja) | 1999-07-09 | 2001-01-23 | Nagase & Co Ltd | ポリ−γ−グルタミン酸の製造方法 |
-
2002
- 2002-08-09 KR KR10-2003-7016665A patent/KR100469800B1/ko not_active Expired - Fee Related
- 2002-08-09 EP EP02755966A patent/EP1421195B1/en not_active Expired - Lifetime
- 2002-08-09 DE DE60215521T patent/DE60215521T2/de not_active Expired - Lifetime
- 2002-08-09 JP JP2003519489A patent/JP4458844B2/ja not_active Expired - Fee Related
- 2002-08-09 AT AT02755966T patent/ATE342990T1/de not_active IP Right Cessation
- 2002-08-09 US US10/484,605 patent/US7553636B2/en not_active Expired - Lifetime
- 2002-08-09 WO PCT/KR2002/001522 patent/WO2003014360A1/en not_active Ceased
- 2002-08-09 CN CNB028153715A patent/CN1311082C/zh not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1311082C (zh) | 2007-04-18 |
| EP1421195A1 (en) | 2004-05-26 |
| JP2005500054A (ja) | 2005-01-06 |
| KR100469800B1 (ko) | 2005-02-02 |
| EP1421195B1 (en) | 2006-10-18 |
| DE60215521D1 (de) | 2006-11-30 |
| ATE342990T1 (de) | 2006-11-15 |
| CN1539018A (zh) | 2004-10-20 |
| WO2003014360A1 (en) | 2003-02-20 |
| US20040253704A1 (en) | 2004-12-16 |
| KR20040032824A (ko) | 2004-04-17 |
| EP1421195A4 (en) | 2005-04-27 |
| DE60215521T2 (de) | 2007-06-21 |
| US7553636B2 (en) | 2009-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4458844B2 (ja) | pgsBCA、ポリ−γ−グルタミン酸シンテターゼをコードする遺伝子を有する表面発現用のベクター、及びこれを用いた標的タンパク質の微生物表面発現方法 | |
| CN103396478B (zh) | 来自原核细胞的重组n-糖基化蛋白 | |
| EP0746621B1 (en) | Expression of proteins on bacterial surface | |
| JP2011172599A (ja) | シュードモナス・フルオレッセンスにおける哺乳動物タンパク質の発現 | |
| JP2022512617A (ja) | ラクトバチルス・カゼイ由来の二種類のプロモーターを用いた二種の目的タンパク質の同時表面発現ベクター、およびこれを用いたタンパク質の微生物表面発現方法 | |
| CA2222128C (en) | Surface anchoring vector and system for foreign proteins thereof | |
| JP2005528085A (ja) | 修飾された細菌表層タンパク質 | |
| CN1216065A (zh) | 重组蛋白的运出系统 | |
| WO2002055561A1 (en) | Method for surface display of proteins on genetic carriers | |
| KR100690948B1 (ko) | 대장균의 외막 단백질을 이용한 목적 단백질의 미생물표면발현 방법 | |
| CN112334580B (zh) | 利用源自芽孢杆菌菌株的聚γ-谷氨酸合成基因的表面表达载体以及使用该载体在微生物表面表达蛋白的方法 | |
| KR20000064592A (ko) | 재조합단백질용엑스포트시스템 | |
| DK1144590T3 (en) | Compartmentalization of recombinant polypeptides in host cells | |
| JP2022504335A (ja) | ラクトバチルス・カゼイ由来ガラクトース・ムタロターゼ遺伝子のプロモーターを用いた常時的高発現表面発現ベクターおよびその利用 | |
| KR20000006448A (ko) | 빙핵활성단백질을이용한B형간염바이러스표면항원과C형간염바이러스의코아(core)항원의표면발현방법 | |
| KR20000006463A (ko) | 빙핵활성단백질을이용한B형간염바이러스표면항원과C형간염바이러스의코아(core)항원의표면발현방법 | |
| HK40059531A (en) | Surface expression vector for constitutive high- expression using promoter of galactose mutarotase gene derived from lactobacillus casei, and use thereof | |
| KR20210081195A (ko) | 락토바실러스 카제이 유래 갈락토오스 뮤타로테이즈 유전자의 프로모터를 이용한 항시적 고발현 표면발현벡터 및 그 이용 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041025 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20041025 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041025 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20041025 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071016 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080116 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080123 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080218 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080225 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080317 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080325 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080416 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090707 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091109 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100104 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100119 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100209 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4458844 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130219 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140219 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |